Current status and perspectives of immune-based therapies for hepatocellular carcinoma
Maridi Aerts, Hendrik Reynaert, University hospital, UZ Brussel, Department of Gastroenterology and Hepatology, 1090 Brussels, Belgium
Daphné Benteyn, Kris Thielemans, Vrije Universiteit Brussel (VUB), Department of Immunology, 1090 Brussels, Belgium
Hans Van Vlierberghe, UZ Gent, Department of Gastroenterology and Hepatology, De Pinte laan, 9000 Ghent, Belgium
Author contributions: Aerts M, Benteyn D and Reynaert H analyzed the literature and wrote the manuscript; Van Vlierberghe H and Thielemans K critically revised the manuscript.; all authors approved the final version of the manuscript.
Supported by Grant from Kankerplan Action 29, Ministry of health, Belgium (to Aerts M); Van Vlierberghe H is senior researcher of the Flemish Fund for Research (FWO).
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hendrik Reynaert, MD, PhD, Professor, University hospital, UZ Brussel, Department of Gastroenterology and Hepatology, Laarbeeklaan 101, 1090 Brussels, Belgium. firstname.lastname@example.org
Telephone: +32-2-4776811 Fax: +32-2-4776810
Received: June 8, 2015
Peer-review started: June 11, 2015
First decision: July 14, 2015
Revised: August 11, 2015
Accepted: October 26, 2015
Article in press: October 26, 2015
Published online: January 7, 2016